AbbVie Could Face Patent Battle Over Depression Asset Gained in Gilgamesh Deal [SeekingAlpha]
Wednesday, October 15, 2025 1 min read
Key Takeaway: Enveric Biosciences is considering legal action against AbbVie, claiming that AbbVie's candidate for major depressive disorder, bretisilocin, infringes on a patent held by Enveric. This candidate was part of a deal AbbVie made with Gilgamesh Pharmaceuticals for up to $1.2 billion. The situation may complicate AbbVie's plans in the depression treatment market.
Price reaction · baseline $8.6856 (2025-10-14 close) · hit pre-market · 2 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+24.4%
day 1
+8.9%
day 3
-1.5%
Market Sentiment Analysis
CONCERNS & RISKS
Enveric Biosciences is threatening legal action against AbbVie.
AbbVie may face a patent infringement lawsuit regarding bretisilocin.
The potential legal battle could impact AbbVie's acquisition strategy.
Full Press Release Details
Microcap Enveric Biosciences (NASDAQ:ENVB) is threatening to take legal action against AbbVie (NYSE:ABBV) as it believes that the latter’s major depressive disorder candidate bretisilocin, which it said it would acquire from Gilgamesh Pharmaceuticals in August for up to $1.2B, infringes on a patent it holds.
Full Article >>
Frequently Asked Questions
What is the reason for Enveric's legal threat against AbbVie?
Enveric claims that AbbVie's bretisilocin infringes on a patent it holds.
How much did AbbVie pay for the Gilgamesh deal?
AbbVie agreed to acquire the asset for up to $1.2 billion.
What condition is bretisilocin targeting?
Bretisilocin is a candidate for treating major depressive disorder.
What could be the impact of this legal action?
The lawsuit could complicate AbbVie's acquisition strategy and market plans.